Navigation Links
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Date:5/28/2009

nt plans, the potential safety and efficacy of its products in development and commercialization strategy. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Report on Form 10-Q for the period ended March 31, 2009, which was filed with the SEC on May 11, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

(1) American Cancer Society, Cancer Facts and Figures 2008


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
2. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
3. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
4. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
5. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
6. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
7. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
8. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
9. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
10. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 Endo International plc (NASDAQ: ... revenues of $719 million, an increase of 1 percent ... Endo reported net income of $21 million in the ... million in the second quarter of 2013.  As detailed ... for the three months ended June 30, 2014 increased by ...
(Date:7/31/2014)... July 31, 2014 Marken announced today the ... to meet the clinical trial logistics growth in Central ... expanded facility will continue to serve as a regional ... and from the region, and will provide additional storage ... will combine its office and warehouse into a single ...
(Date:7/31/2014)... , 31 juli 2014 De Pfizer ... een rekruteringscampagne voor gezonde vrijwilligers van Japanse komaf voor ... gevestigde PCRU is één van twee onderzoekseenheden ... als ideaal levens te verbeteren door de ontdekking en ... de PCRU op zoek naar mannen en vrouwen van ...
Breaking Medicine Technology:Endo Reports Second Quarter Financial Results 2Endo Reports Second Quarter Financial Results 3Endo Reports Second Quarter Financial Results 4Endo Reports Second Quarter Financial Results 5Endo Reports Second Quarter Financial Results 6Endo Reports Second Quarter Financial Results 7Endo Reports Second Quarter Financial Results 8Endo Reports Second Quarter Financial Results 9Endo Reports Second Quarter Financial Results 10Endo Reports Second Quarter Financial Results 11Endo Reports Second Quarter Financial Results 12Endo Reports Second Quarter Financial Results 13Endo Reports Second Quarter Financial Results 14Endo Reports Second Quarter Financial Results 15Endo Reports Second Quarter Financial Results 16Endo Reports Second Quarter Financial Results 17Endo Reports Second Quarter Financial Results 18Endo Reports Second Quarter Financial Results 19Endo Reports Second Quarter Financial Results 20Endo Reports Second Quarter Financial Results 21Endo Reports Second Quarter Financial Results 22Endo Reports Second Quarter Financial Results 23Endo Reports Second Quarter Financial Results 24Endo Reports Second Quarter Financial Results 25Endo Reports Second Quarter Financial Results 26Endo Reports Second Quarter Financial Results 27Endo Reports Second Quarter Financial Results 28Endo Reports Second Quarter Financial Results 29Endo Reports Second Quarter Financial Results 30Endo Reports Second Quarter Financial Results 31Endo Reports Second Quarter Financial Results 32Marken Expands Miami Regional Logistics Center 2Gezonde vrijwilligers van Japanse komaf gezocht voor deelname aan Fase I klinisch onderzoek 2
... Genetic Technologies Limited (ASX: GTG; NASDAQ: ... agreement to jointly develop a new cancer profiling product ... Under the collaboration Genetic Technologies will use ... world-leading pharmaceutical company to develop specific and novel genetic ...
... If your medicine has expired, it may not provide ... FDA pharmacist Ilisa Bernstein explains how expiration dates help ... work as intended. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) ... Sign up for e-mail notices of new FDA Consumer ...
Cached Medicine Technology:GTG Announces New Product Collaboration with Global Pharmaceutical Company for Companion Diagnostics in Oncology 2
(Date:7/31/2014)... (PRWEB) July 31, 2014 T.E.N., ... relationship-marketing firm, honored finalists and winners Wednesday evening, ... Forum and Awards Gala at the Westin St. ... director of information security for the BlackLine Systems, ... the Year Award winner for the ISE® West ...
(Date:7/31/2014)... Amy Norton HealthDay ... Babies born with so-called "bubble boy" disease can often be ... -- but early treatment is critical, a new study finds. ... known, actually refers to a group of rare genetic disorders ... at high risk of severe infections. The term "bubble ...
(Date:7/31/2014)... 31, 2014 (HealthDay News) -- Recovery time after surgery ... known as statins, according to a new study. ... affect the body,s inflammatory response, reducing the amount of ... seemed to be particularly true among people who tend ... of the most widely prescribed medications in the world. ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 ... to reach $702m by 2020, increasing slowly ... market will be driven by: the rising ... incurred by government agencies, such as Medicare, ... adoption of innovative technologies such as flow ...
(Date:7/31/2014)... July 31, 2014 -- A new study by researchers ... a peptide called caerulein can convert existing cells in ... diabetes-insulin-producing beta cells. The study, published online July 31 ... new approach to treating the estimated 3 million people ... with type 1 diabetes. , "We have found a ...
Breaking Medicine News(10 mins):Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 3Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 4Health News:Early Stem Cell Transplant Vital in 'Bubble Boy' Disease 2Health News:Early Stem Cell Transplant Vital in 'Bubble Boy' Disease 3Health News:Cholesterol Drugs May Speed Healing After Surgery 2Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:US Neurovascular Interventions Market Worth $702m by 2020 Says a New Report Available at MarketOptimizer.org 5Health News:A new way to generate insulin-producing cells in Type 1 diabetes 2
... to be Delayed, CAMBRIDGE, Mass., Nov. 13 ... has received a letter from the U.S.,Food and Drug ... for Synvisc-One(TM) in the United,States. The company now expects ... be delayed in the U.S. until at least the,second ...
... to avoid may offer protection , TUESDAY, Nov. 13 (HealthDay ... meats may help improve the chances of surviving a heart ... of a preliminary study in the Nov. 12 online edition ... . , Researchers found that mice fed extra nitrite ...
... house,abandoned older pets, who spend their last days watching ... kittens. November is Adopt-a-Senior-Pet Month and is dedicated ... and the fulfillment they can bring to the,right owner. ... these animals have been,surrendered," said Brent Hinton, former Kentucky ...
... water work,well for simple cleaning, they won,t do the ... illness. Something stronger must be used. U.S. Nonwovens ... this pressing problem. Rediwipes are proven to kill,99.9 percent ... "The first cardinal rule of safe food preparation in ...
... Inc.,(Nasdaq: CLRT ), a premier technology and ... today announced,that it was ranked #19 on Deloitte,s ... was also named to Deloitte,s 2007 Technology Fast ... Fast 50 is a ranking of the 50,fastest ...
... - No Human Vaccine Currently Exists Against the ... Deaths in the US so far in 2007;,Collaboration Aims ... as Rapidly as Possible Acambis plc (Acambis) (LSE: ... has signed an exclusive global,collaboration agreement with Sanofi Pasteur, ...
Cached Medicine News:Health News:Genzyme Receives FDA Response Letter on Synvisc-One(TM) 2Health News:Genzyme Receives FDA Response Letter on Synvisc-One(TM) 3Health News:Nitrite, Nitrate-Rich Foods Boost Heart Attack Outcomes 2Health News:Old Dogs Can Learn New Tricks 2Health News:Disinfecting Rediwipes(TM) Launch Targets E. coli and Salmonella 2Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 2Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 3Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 4Health News:Clarient Named to Deloitte's 2007 Orange County Technology Fast 50 for Third Consecutive Year 5Health News:Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine 2Health News:Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine 3Health News:Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine 4
Complete cytology platform....
... is the first in portability and performance. CTU ... need a flexible, portable system with the state-of-the-art features ... easily to an "E" size tank and has an ... where it is needed.,The CTU Travel Case allows you ...
The most compact revolutionary innovation in hematology. 26 parameters with 5 Part DIFF...
... Total GHb Program separates ... hemoglobin regardless of phenotype ... Schiff Base. Patient results ... DCCT reference to ensure ...
Medicine Products: